肝素诱导的血小板减少症患者的脑静脉血栓形成:系统综述
该系统综述检索了截至2021年6月1日的文献,纳入23个HIT病例系列(n=1220)及27例HIT相关CVT病例,发现HIT患者中CVT发生率为1.6%(95%CI 1.0%-2.5%,I²=0%),HIT相关CVT的院内死亡率为33.3%,较历史CVT对照的4.3%绝对增加29%(P<0.001),较无CVT的HIT患者15.9%超额死亡17.4%(P=0.046)。
要点
- HIT患者中CVT发生率为1.6%(95%CI 1.0%-2.5%,I²=0%)。
- HIT相关CVT中出血性脑病变占81.8%,其他血管区域并发血栓形成占47.8%。
- HIT相关CVT院内死亡率为33.3%,较历史CVT对照的4.3%绝对增加29%(P<0.001)。
核心结论
- CVT是HIT患者中罕见的血栓表现。
- 与历史对照的CVT相比,HIT相关CVT的脑出血率和死亡风险更高。
- HIT中未观察到疫苗诱导的血栓性血小板减少症中近期报道的高频率CVT,提示除抗血小板因子4抗体外,疫苗诱导的血栓性血小板减少症相关CVT可能涉及其他病理生理机制。
研究设计与样本
- 研究方案在PROSPERO注册(CRD42021249652)。
- 检索MEDLINE、EMBASE和Cochrane CENTRAL至2021年6月1日,纳入包含>20例患者的HIT病例系列或任何HIT相关CVT的报告。
- 从19073条结果中选出23个HIT病例系列(n=1220)和27例HIT相关CVT病例(n=27,71%为女性)。
- 采用随机效应模型的比例Meta分析得出HIT中CVT发生率和院内死亡率。
- 将汇总估计值与无HIT的CVT及无CVT的HIT比较,以确定死亡率差异。
主要发现
- 1220例HIT患者中CVT发生率为1.6%(95%CI 1.0%-2.5%,I²=0%)。
- HIT相关CVT病例中出血性脑病变占81.8%,其他血管区域并发血栓形成占47.8%。
- HIT相关CVT的院内死亡率为33.3%。
- HIT相关CVT较历史CVT对照的死亡率绝对增加29%(33.3% vs 4.3%,P<0.001)。
- HIT相关CVT较无CVT的HIT患者超额死亡17.4%(33.3% vs 15.9%,P=0.046)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebral venous thrombosis (CVT) has recently been reported as a common thrombotic manifestation in association with vaccine-induced thrombotic thrombocytopenia, a syndrome that mimics heparin-induced thrombocytopenia (HIT) and occurs after vaccination with adenovirus-based SARS-CoV-2 vaccines. We aimed to systematically review the incidence, clinical features, and prognosis of CVT occurring in patients with HIT. METHODS: The study protocol was registered with PROSPERO (CRD42021249652). MEDLINE, EMBASE and Cochrane CENTRAL were searched up to June 1, 2021 for HIT case series including >20 patients, or any report of HIT-related CVT. Demographic, neuroradiological, clinical, and mortality data were retrieved. Meta-analysis of proportions with random-effect modeling was used to derive rate of CVT in HIT and in-hospital mortality. Pooled estimates were compared with those for CVT without HIT and HIT without CVT, to determine differences in mortality. RESULTS: From 19073 results, we selected 23 case series of HIT (n=1220) and 27 cases of HIT-related CVT (n=27, 71% female). CVT developed in 1.6% of 1220 patients with HIT (95% CI,1.0%-2.5%, I2=0%). Hemorrhagic brain lesions occurred in 81.8% of cases of HIT-related CVT and other concomitant thrombosis affecting other vascular territory was reported in 47.8% of cases. In-hospital mortality was 33.3%. HIT-related CVT carried a 29% absolute increase in mortality rate compared with historical CVT controls (33.3% versus 4.3%, P<0.001) and a 17.4% excess mortality compared with HIT without CVT (33.3% versus 15.9%, P=0.046). CONCLUSIONS: CVT is a rare thrombotic manifestation in patients with HIT. HIT-related CVT has higher rates of intracerebral hemorrhage and a higher mortality risk, when compared with CVT in historical controls. The recently reported high frequency of CVT in patients with vaccine-induced thrombotic thrombocytopenia was not observed in HIT, suggesting that additional pathophysiological mechanisms besides anti-platelet factor-4 antibodies might be involved in vaccine-induced thrombotic thrombocytopenia-related CVT.
引用
- Aguiar de Sousa D, Romoli M, Sánchez Van Kammen M, et al. Cerebral Venous Thrombosis in Patients With Heparin-Induced Thrombocytopenia a Systematic Review. Stroke. 2022. PMID: 35240862. doi:10.1161/STROKEAHA.121.036824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。